Roles of the histone acetyltransferase monocytic leukemia zinc finger protein in normal and malignant hematopoiesis

Cancer Science

Volumn 99, Issue 8, 2008, Pages 1523-1527

  Katsumoto, Takuo ^a   Yoshida, Naomi ^a   Kitabayashi, Issay ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM BINDING PROTEIN; DIAZEPAM BINDING INHIBITOR; HISTONE ACETYLTRANSFERASE; HYBRID PROTEIN; MONOCYTIC LEUKEMIA ZINC FINGER PROTEIN; NUCLEAR RECEPTOR COACTIVATOR 2; PROTEIN MOZ; PROTEIN P300; PROTEIN P53; PROTEIN RET; TRANSCRIPTION FACTOR PU 1; TRANSCRIPTION FACTOR RUNX1; ZINC FINGER PROTEIN;

ACETYLATION; ACUTE GRANULOCYTIC LEUKEMIA; CELL RENEWAL; CHROMOSOME TRANSLOCATION; FUSION GENE; GENE EXPRESSION; GENE TRANSLOCATION; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HISTONE ACETYLATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; CELL DEATH; CELL DIFFERENTIATION; CELL PROLIFERATION; GENE EXPRESSION; GENE FUSION; HEMATOPOIESIS; HISTONE ACETYLTRANSFERASES; HUMANS; LEUKEMIA, MYELOID; MICE;

EID: 49749104565     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2008.00865.x     Document Type: Review

References (59)

1. Look AT. Oncogenic transcription factors in the human acute leukemias. Science 1997; 278: 1059-64.
2. Mrozek K, Heinonen K, Bloomfield CD. Clinical importance of cytogenetics in acute myeloid leukaemia. Best Pract Res Clin Haematol 2001; 14: 19-47.
3. Scandura JM, Boccuni P, Cammenga J, Nimer SD. Transcription factor fusions in acute leukemia: Variations on a theme. Oncogene 2002; 21: 3422-44.
4. Di Croce L. Chromatin modifying activity of leukaemia associated fusion proteins. Hum Mol Genet 2005; 14 (Spec 1): R77-84.
5. Kitabayashi I, Aikawa Y, Nguyen LA, Yokoyama A, Ohki M. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. Embo J 2001; 20: 7184-96.
6. Champagne N, Pelletier N, Yang XJ. The monocytic leukemia zinc finger protein MOZ is a histone acetyltransferase. Oncogene 2001; 20: 404-9.
7. Thomas T, Corcoran LM, Gugasyan R et al. Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells. Genes Dev 2006; 20: 1175-86.
8. Katsumoto T, Aikawa Y, Iwama A et al. MOZ is essential for maintenance of hematopoietic stem cells. Genes Dev 2006; 20: 1321-30.
9. Deguchi K, Ayton PM, Carapeti M et al. MOZ-TIF2-induced acute myeloid leukemia requires the MOZ nucleosome binding motif and TIF2-mediated recruitment of CBP. Cancer Cell 2003; 3: 259-71.
10. Huntly BJ, Gilliland DG. Leukaemia stem cells and the evolution of cancer-stem-cell research. Nat Rev Cancer 2005; 5: 311-21.
11. Borrow J, Stanton VP Jr, Andresen JM et al. The translocation t(8;16) (p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 1996; 14: 33-41.
12. Chaffanet M, Gressin L, Preudhomme C, Soenen-Cornu V, Birnbaum D, Pebusque MJ. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer 2000; 28: 138-44.
13. Kitabayashi I, Aikawa Y, Yokoyama A et al. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22) (p11;q13) chromosome translocation. Leukemia 2001; 15: 89-94.
14. Carapeti M, Aguiar RC, Goldman JM, Cross NC. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 1998; 91: 3127-33.
15. Liang J, Prouty L, Williams BJ, Dayton MA, Blanchard KL. Acute mixed lineage leukemia with an inv (8) (p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood 1998; 92: 2118-22.
16. Esteyries S, Perot C, Adelaide J et al. NCOA3, a new fusion partner for MOZ/MYST3 in M5 acute myeloid leukemia. Leukemia 2007; 22: 663-5.
17. Imamura T, Kakazu N, Hibi S et al. Rearrangement of the MOZ gene in pediatric therapy-related myelodysplastic syndrome with a novel chromosomal translocation t(2;8) (p23;p11). Genes Chromosomes Cancer 2003; 36: 413-19.
18. Yang XJ, Ullah M. MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. Oncogene 2007; 26: 5408-19.
19. Thomas T, Voss AK, Chowdhury K, Gruss P. Querkopf, a MYST family histone acetyltransferase, is required for normal cerebral cortex development. Development 2000; 127: 2537-48.
20. Panagopoulos I, Fioretos T, Isaksson M et al. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16) (q22;p13). Hum Mol Genet 2001; 10: 395-404.
21. Vizmanos JL, Larrayoz MJ, Lahortiga I et al. t(10;16) (q22;p13) and MORF-CREBBP fusion is a recurrent event in acute myeloid leukemia. Genes Chromosomes Cancer 2003; 36: 402-5.
22. Kojima K, Kaneda K, Yoshida C et al. A novel fusion variant of the MORF and CBP genes detected in therapy-related myelodysplastic syndrome with t(10;16) (q22;p13). Br J Haematol 2003; 120: 271-3.
23. Moore SD, Herrick SR, Ince TA et al. Uterine leiomyomata with t(10;17) disrupt the histone acetyltransferase MORF. Cancer Res 2004; 64: 5570-7.
24. Iyer NG, Ozdag H, Caldas C. p300/CBP and cancer. Oncogene 2004; 23: 4225-31.
25. Xu J, Li Q. Review of the in vivo functions of the p160 steroid receptor coactivator family. Mol Endocrinol 2003; 17: 1681-92.
26. Akhtar A, Becker PB. The histone H4 acetyltransferase MOF uses a C2HC zinc finger for substrate recognition. EMBO Rep 2001; 2: 113-8.
27. Holbert MA, Sikorski T, Carten J, Snowflack D, Hodawadekar S, Marmorstein R. The human monocytic leukemia zinc finger histone acetyltransferase domain contains DNA-binding activity implicated in chromatin targeting. J Biol Chem 2007; 282: 36603-13.
28. Struhl K. Histone acetylation and transcriptional regulatory mechanisms. Genes Dev 1998; 12: 599-606.
29. Yang XJ. The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucl Acids Res 2004; 32: 959-76.
30. Doyon Y, Cayrou C, Ullah M et al. ING tumor suppressor proteins are critical regulators of chromatin acetylation required for genome expression and perpetuation. Mol Cell 2006; 21: 51-64.
31. Avvakumov N, Cote J. The MYST family of histone acetyltransferases and their intimate links to cancer. Oncogene 2007; 26: 5395-407.
32. Pelletier N, Champagne N, Stifani S, Yang XJ. MOZ and MORF histone acetyltransferases interact with the Runt-domain transcription factor Runx2. Oncogene 2002; 21: 2729-40.
33. Chan EM, Chan RJ, Comer EM et al. MOZ and MOZ-CBP cooperate with NF-kappaB to activate transcription from NF-kappaB-dependent promoters. Exp Hematol 2007; 35: 1782-92.
34. Kitabayashi I, Yokoyama A, Shimizu K, Ohki M. Interaction and functional cooperation of the leukemia-associated factors AML1 and p300 in myeloid cell differentiation. Embo J 1998; 17: 2994-3004.
35. Nguyen LA, Pandolfi PP, Aikawa Y, Tagata Y, Ohki M, Kitabayashi I. Physical and functional link of the leukemia-associated factors AML1 and PML. Blood 2005; 105: 292-300.
36. Aikawa Y, Nguyen LA, Isono K et al. Roles of HIPK1 and HIPK2 in AML1- and p300-dependent transcription, hematopoiesis and blood vessel formation. Embo J 2006; 25: 3955-65.
37. Yoshida H, Kitabayashi I. Chromatin regulation by AML1 complex. Int J Hematol 2008; 87: 19-24.
38. Bristow CA, Shore P. Transcriptional regulation of the human MIP-1alpha promoter by RUNX1 and MOZ. Nucl Acids Res 2003; 31: 2735-44.
39. Ohta K, Ohigashi M, Naganawa A et al. Histone acetyltransferase MOZ acts as a co-activator of Nrf2-MafK and induces tumour marker gene expression during hepatocarcinogenesis. Biochem J 2007; 402: 559-66.
40. Miller CT, Maves L, Kimmel CB. moz regulates Hox expression and pharyngeal segmental identity in zebrafish. Development 2004; 131: 2443-61.
41. Crump JG, Swartz ME, Eberhart JK, Kimmel CB. Moz-dependent Hox expression controls segment-specific fate maps of skeletal precursors in the face. Development 2006; 133: 2661-9.
42. Camos M, Esteve J, Jares P et al. Gene expression profiling of acute myeloid leukemia with translocation t(8;16) (p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res 2006; 66: 6947-54.
43. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR. AML1, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 1996; 84: 321-30.
44. Ichikawa M, Asai T, Saito T et al. AML-1 is required for megakaryocytic maturation and lymphocytic differentiation, but not for maintenance of hematopoietic stem cells in adult hematopoiesis. Nat Med 2004; 10: 299-304.
45. Growney JD, Shigematsu H, Li Z et al. Loss of Runx1 perturbs adult hematopoiesis and is associated with a myeloproliferative phenotype. Blood 2005; 106: 494-504.
46. Putz G, Rosner A, Nuesslein I, Schmitz N, Buchholz F. AML1 deletion in adult mice causes splenomegaly and lymphomas. Oncogene 2006; 25: 929-39.
47. Kim HG, de Guzman CG, Swindle CS et al. The ETS family transcription factor PU.1 is necessary for the maintenance of fetal liver hematopoietic stem cells. Blood 2004; 104: 3894-900.
48. Iwasaki H, Somoza C, Shigematsu H et al. Distinctive and indispensable roles of PU.1 in maintenance of hematopoietic stem cells and their differentiation. Blood 2005; 106: 1590-600.
49. Nutt SL, Metcalf D, D'Amico A, Polli M, Wu L. Dynamic regulation of PU.1 expression in multipotent hematopoietic progenitors. J Exp Med 2005; 201: 221-31.
50. Rosenbauer F, Wagner K, Kutok JL et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU. 1 Nat Genet 2004; 36: 624-30.
51. Stein MI, Zhu J, Emerson SG. Molecular pathways regulating the self-renewal of hematopoietic stem cells. Exp Hematol 2004; 32: 1129-36.
52. Huang X, Cho S, Spangrude GJ. Hematopoietic stem cells: Generation and self-renewal. Cell Death Differ 2007;14: 1851-9.
53. Lawrence HJ, Christensen J, Fong S et al. Loss of expression of the HOXA-9 homeobox gene impairs the proliferation and repopulating ability of hematopoietic stem cells. Blood 2005; 106: 3988-94.
54. Waskow C, Paul S, Haller C, Gassmann M, Rodewald HR. Viable c-Kit (W/W) mutants reveal pivotal role for c-kit in the maintenance of lymphopoiesis. Immunity 2002; 17: 277-88.
55. Kimura S, Roberts AW, Metcalf D, Alexander WS. Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin. Proc Natl Acad Sci USA 1998; 95: 1195-200.
56. Antonchuk J, Hyland CD, Hilton DJ, Alexander WS. Synergistic effects on erythropoiesis, thrombopoiesis, and stem cell competitiveness in mice deficient in thrombopoietin and steel factor receptors. Blood 2004; 104: 1306-13.
57. Huntly BJ, Shigematsu H, Deguchi K et al. MOZ-TIF2, but not BCR-ABL, confers properties of leukemic stem cells to committed murine hematopoietic progenitors. Cancer Cell 2004; 6: 587-96.
58. Kindle KB, Troke PJ, Collins HM et al. MOZ-TIF2 inhibits transcription by nuclear receptors and p53 by impairment of CBP function. Mol Cell Biol 2005; 25: 988-1002.
59. Eklund EA. The role of HOX genes in malignant myeloid disease. Curr Opin Hematol 2007; 14: 85-9.